Home GPCR & G Protein Taste Receptor agonist - TNF-alpha inhibitor - Apoptosis related activator - PI3K inhibitor - Akt inhibitor - AMPK activator Amarogentin For research use only.

Amarogentin

Synonyms: AG

Amarogentin (AG), a secoiridoid glycoside mainly extracted from Swertia and Gentiana roots, exhibits anti-oxidative, anti-tumour, and anti-diabetic activities. Amarogentin is an agonist for the bitter taste receptor TAS2R1 and inhibits in LAD-2 cells substance P-induced production of newly synthesized TNF-α. Amarogentin induces apoptosis in human gastric cancer cells (SNU-16) through G2/M cell cycle arrest and PI3K/Akt signalling pathway. Amarogentin (AG) interacts with the α2 subunit of AMP-activated protein kinase (AMPK) and activates the trimeric kinase with EC50 of 277 pM.

Amarogentin Chemical Structure

Amarogentin Chemical Structure

CAS No. 21018-84-8

Purity & Quality Control

Batch: S127301 DMSO]100 mg/mL]false]Ethanol]50 mg/mL]false]Water]Insoluble]false Purity: 99.17%
99.17

Amarogentin Related Products

Biological Activity

Description

Amarogentin (AG), a secoiridoid glycoside mainly extracted from Swertia and Gentiana roots, exhibits anti-oxidative, anti-tumour, and anti-diabetic activities. Amarogentin is an agonist for the bitter taste receptor TAS2R1 and inhibits in LAD-2 cells substance P-induced production of newly synthesized TNF-α. Amarogentin induces apoptosis in human gastric cancer cells (SNU-16) through G2/M cell cycle arrest and PI3K/Akt signalling pathway. Amarogentin (AG) interacts with the α2 subunit of AMP-activated protein kinase (AMPK) and activates the trimeric kinase with EC50 of 277 pM.
Targets
TAS2R1 [2] TNF-α [2] AMPK [4]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06298474 Not yet recruiting
Dementia|Alzheimer Disease|Vascular Dementia
Hopeful Aging
 February 15 2025 Not Applicable
NCT06045988 Not yet recruiting
Alzheimer Disease|Dementia|Sleep Disturbance
Indiana University|Innovative Design Labs|University of Minnesota|Mayo Clinic|Regenstrief Institute Inc.|National Institute on Aging (NIA)
 February 1 2025 Phase 2
NCT06117176 Not yet recruiting
Airway Complication of Anesthesia|Adverse Events
Insel Gruppe AG University Hospital Bern|University of Bern|University of Lausanne Hospitals|Kantonsspital Aarau|Charite University Berlin Germany|Universitätsklinikum Hamburg-Eppendorf
 January 2025 --
NCT05940766 Not yet recruiting
Pediatric Oncology Patients With Risk for Infections
Insel Gruppe AG University Hospital Bern|ETH Zurich
 October 1 2024 Not Applicable
NCT06370572 Not yet recruiting
Dementia|Hip Pain|Emergency Department Patient|Pain in Advanced Dementia Scale
University of Chicago|National Institute on Aging (NIA)|University of North Carolina Chapel Hill
 August 2024 Not Applicable
NCT05457725 Not yet recruiting
Neurocognitive Disorders|Aging|Cognitive Change
University of Florida|National Institute on Aging (NIA)
 July 1 2024 Early Phase 1

Chemical Information & Solubility

Molecular Weight 586.54 Formula

C29H30O13
CAS No. 21018-84-8 SDF --
Smiles OCC1OC(OC2OC=C3C(CCOC3=O)C2C=C)C(OC(=O)C4=C(O)C=C(O)C=C4C5=CC=CC(=C5)O)C(O)C1O
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 100 mg/mL ( (170.49 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 50 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Amarogentin | Amarogentin supplier | purchase Amarogentin | Amarogentin cost | Amarogentin manufacturer | order Amarogentin | Amarogentin distributor